Hack Corona Initiative

Help Memo Therapeutics AG to identify therapeutic monoclonal antibodies against SARS-CoV-2

 

During the course of infection with COVID-19, patients develop antibodies against the virus. Most of them are non-functional but some very rare show exceptional functionality: These antibodies can be utilized to find therapies as well as vaccines.

Memo Therapeutics AG, an ETH-Spin off in Schlieren, has a proprietary technology to find analyze and develop therapeutic candidates from these ultra rare and optimal antibodies from patients. We would like to utilize our technology and help finding a cure against this viral threat.

Who can participate?

  • Healthy persons that have overcome a heavy infection with COVID-19
  • Age: 18 – 80
  • Place: Zurich

What do we require?

  • 30 ml of blood (10 x less than in a normal blood donation)
  • Duration: ca. 1 hour

Compensation: 50 CHF + swiss chocolate

 

To participate, please contact us via E-mail :

corona@memo-therapeutics.com

 

Comprehensive analysis of the antibody repertoires of patients who have recovered from SARS-CoV-2 infection. Discovery of neutralizing antibodies for the development of therapeutic antibodies and rational vaccine strategies

 

Our approach aims at studying the antibody responses to SARS-CoV-2 of selected donors who were able to overcome the infection. Antibodies are small protein molecules produced by our immune system during an infection and have the role to bind the virus and prevent virus entry into cells.

 

The ultimate goal of our program will be to identify the most potent antibodies from convalescent donors and to develop these as a prophylactic therapy option for people at high risk e.g. elderly with additional co-morbidities.

 

Our technology is capable of copying the antibody genetic information of millions of human B cells, the antibody factories of our body, into laboratory workhorse cells. These cells are then used to identify antibodies that neutralize Coronavirus. The technology has been developed by Memo Therapeutics and ETH Zurich and is relying on state of the art microfluidic single cell technology. Memo Therapeutics has recently been successful in isolating extremely potent polyoma virus-neutralizing antibodies from healthy donors and kidney transplant recipients and will used the experience and research infrastructure gained through this project also for Coronavirus.

 

The project will be carried out in Switzerland.